Search

AIM A recent randomised controlled trial showed significant benefits for Parkinson's disease (PD) caregivers' psychosocial problems and need for help and a trend towards significant improvement of patients' quality of life after participation in the Patient Education Programme for Parkinson's disease (PEPP). Large variations in change scores were found, indicating variation in benefit. The aim of this study was to search for treatment effect modifiers. METHODS Outcome measures were patients' quality of life [Parkinson's Disease Questionnaire (PDQ)-39] and caregivers' psychosocial burden [Belastungsfragebogen Parkinson Angehorigen kurzversion (BELA-A-k)]. Candidate treatment effect modifiers were participants' characteristics and baseline scores on psychological questionnaires (BELA-P/A-k, PDQ-39, EQ-5D, Self-rating Depression Scale) and patients' neuropsychological test scores (Mini Mental State Examination, National Adult Reading Test, Dutch version, Word Test, Behavioural Assessment of the Dysexecutive Syndrome rule shift, Trail Making Test, Stroop). Secondary analyses of data from a randomised controlled trial with 64 patients and 46 caregivers were performed using regression analyses with treatment group interaction terms. RESULTS No significant modifiers were found for the patients. In the caregiver group, a higher MMSE score of the patient at baseline was found to be a significant predictor of a lower BELA-A-k Bothered by score post-intervention of the caregiver. CONCLUSIONS A potential predictor of treatment benefit was found for caregivers of PD patients with better cognitive functioning. This study did not find treatment effect modifiers for PD patients: demographics, disease stage and time of diagnosis, cognitive functioning, level of baseline psychosocial burden, participating with or without a caregiver, and caregiver changes did not influence treatment outcome. The PEPP seems suitable for the majority of patients.

Summary Aim: The Patient Education Programme for Parkinson’s disease (PEPP) was assessed in a recent randomised controlled trial (RCT). In this study, a trend was identified towards significant improvement of patients’ quality of life (Qol) as well as a significant reduction of caregivers’ psychosocial burden and need for help. This study is aimed at evaluating the effectiveness of the PEPP in clinical practice as compared with the RCT in an academic setting. The second aim is to assess its effectiveness in clinical practice at 6-month follow-up. Methods: Fifty-five patients and 50 caregivers from nine clinical settings participated in the PEPP consisting of eight weekly sessions of 90 min. Self-report questionnaires were used to assess patients’ Qol (PDQ-39) and caregivers’ psychosocial burden and need for help (BELA-A-k) at baseline, directly after the programme and at 6-month follow-up. To compare the baseline data and short-term effects, data were used from an RCT study which included 64 Parkinson’s disease patients and 46 caregivers. Results: Compared with the RCT control group, significant effects, after Bonferoni adjustment, were found for patients’ Qol as well as for caregivers’ psychosocial burden and need for help. No significant changes were found between baseline scores compared with 6-month follow-up. Scores returned to baseline levels at 6-month follow-up. Conclusions: Effects from the RCT study were replicated and the effect on patients’ Qol was now significant. However, at 6-month follow-up, scores returned to baseline levels, indicating the need for some form of a booster session.

In 24 adults and 29 children both with Gilles de la Tourette syndrome and in 24 control adults and 17 control children we studied auditory event-related potentials (ERP's) evoked in 2 different oddball paradigms: a passive listening paradigm (PLP) in which subjects had only to attend tones (260 standards, 40 deviants), followed by an active discrimination paradigm (ADP) in which subjects had to press a microswitch in response to the deviant tones. In the adult Tourette patients the PLP disclosed between 200-300 msec at all derivations (Fz, Cz, Pz, C3, C4, P3, P4) a significantly more negative activity than in the controls. In the Tourette children such a result was only found at Fz. In the ADP the differences between both adult groups disappeared, but the curves of the control children became now significantly more positive than those of the Tourette ones except at C3 and P3. Between 200-300 msec the curves of all 4 groups were significantly less negative in the ADP than in the PLP. This decrease in negativity was significantly larger in the adult Tourette patients than in the adult controls, but in the children groups the reverse occurred. It is hypothesized that the differences in amplitude between patients and controls and between both paradigms are due to differences in amplitude of an endogenous negative component overlapping the exogenous N100-N200 standard curve. Based on this hypothesis the results could suggest that one of the problems in Tourette syndrome is an increased attention to non-relevant stimuli.

The effect of Tiapride on dyskinesia was evaluated in 12 patients with tardive dyskinesia in a double-blind controlled cross-over trial. The effect was measured by a Doppler-radar device and by counting the number of involuntary movements from video-recordings. Besides these methods, subjective assessments were made on analogue scales by family, nurses and attendant doctors. The subjective evaluation appeared to be useless because of many inconsistent answers. The quantitative methods revealed a significant diminution of the involuntary movements in the Tiapride therapy period (P less than 0.01). It appears that tiapride is an effective drug in the treatment of tardive dyskinesia. No clinically important side-effects have been observed. The drug appeared not to induce parkinsonism.